Navigation Links
Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients

New Study Published in the Journal of Rheumatology Examines Quality of Life and Disability in Treatment Failure Gout Patients

EAST BRUNSWICK, N.J., May 5 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today the print publication of the Savient-supported longitudinal observational (non-interventional) study of patients with treatment failure gout (TFG). The objective of the study was to determine the baseline characteristics and natural history of the disease in these patients, who are without treatment options, when under the care of a Board Certified Rheumatologist.

The study is the first to evaluate the quality of life in patients with treatment failure gout and appears in the May issue of the Journal of Rheumatology. TFG is defined as advanced gout in patients where conventional therapy is contraindicated or has been ineffective.

"Our study examined some of the most difficult to treat gout patients, many of whom regularly experience excruciating pain and struggle with co-morbid health disorders like metabolic and cardiovascular disease," said John S. Sundy, MD, PhD, Division of Rheumatology at Duke University Medical Center. "The results from the study provides clear evidence that despite today's best practice, treatment failure gout has a significant impact on health-related quality of life and disability. Many everyday activities even walking, are virtually impossible for many of these patients."

Treatment failure gout was shown to be associated with poor health-related quality of life and significant disability. Validated survey instruments for the assessment of patient-reported quality of life were used in this study which included Health Assessment Questionnaire-Disability Index and the SF-36. The TFG patients that were studied averaged 59 years in age. However, due to the poor quality of life associated with the disease, the reported results were more typical of Americans 74 years or older without TFG. Additionally, patient-reported perceptions of their gout-related pain and functioning were even more severe and more consistent than assessments of these same metrics reported by physicians.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient's product development candidate, KRYSTEXXA(TM) (pegloticase) for treatment failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007. The BLA was filed with the FDA in October 2008; granted priority review status in December 2008; and the review period was extended by three months in February 2009. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the efficacy and safety of KRYSTEXXA(TM) (pegloticase), our BLA filing with the FDA, the Advisory Committee, approval of the BLA, preparation for commercialization of KRYSTEXXA, and the market for KRYSTEXXA, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of KRYSTEXXA and developing other product candidates; our stock price and market conditions; varying interpretations of our clinical and CMC data by the FDA; delay achieving or failure to achieve FDA approval of KRYSTEXXA; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in ongoing or future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.


    Mary Coleman
    Savient Pharmaceuticals, Inc.
    (732) 418-9300

    Christina Gibson
    Euro RSCG Life Worldwide
    (212) 367-6818

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
2. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
3. Cost-Cutting Plus Value-Add Defines Qualitys Role in a Recession
4. PhRMA, Families USA Jointly Promote Measures to Ensure Quality, Affordable Healthcare Coverage
5. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
6. EPA Awards Lovelace Respiratory Research Institute $500,000 for Air Quality Research
7. World's First Website for Patients to Share Diagnostic-Quality Medical Images
8. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
9. AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers
10. Managing Risk Through Quality: Ansell Healthcares Innovative Gammex(R) Glove Range on Display at Arab Health 2009
11. New Initiative Focuses on Water Quality Improvement in the Mississippi River Basin and Gulf of Mexico
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
Breaking Biology News(10 mins):